Development of a platform, based on the unique competence within alpha emitting diagnosis and cancer therapy
The first project is to develop a targeted alpha-particle radio-immunotherapy (TAT) based on astatine conjugated to the monoclonal antibody (MAb) farletuzumab as a new drug for the treatment of ovarian cancer.
